The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 533 KB) and Technical Notes (PDF, 752 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 21.16
Cancer of the Ovary (Invasive)
| Histologya | All Races | White | Black | Asian/ Pacific Islander |
American Indian /Alaska Nativeb |
Hispanicc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Count | Percent | Count | Percent | Count | Percent | Count | Percent | Count | Percent | |
| Carcinoma | 24,578 | 91.7% | 20,563 | 92.2% | 1,912 | 88.3% | 1,824 | 90.3% | 116 | 92.8% | 2,859 | 87.3% |
| Epidermoid carcinomad (8051-8131) | 191 | 0.7% | 149 | 0.7% | 18 | 0.8% | 21 | 1.0% | - | - | 28 | 0.9% |
| Adenocarcinomae | 22,524 | 84.0% | 18,946 | 84.9% | 1,650 | 76.2% | 1,680 | 83.1% | 105 | 84.0% | 2,560 | 78.1% |
| Adenocarcinoma, NOS (8140) | 3,291 | 12.3% | 2,679 | 12.0% | 403 | 18.6% | 183 | 9.1% | - | - | 323 | 9.9% |
| Papillary adenocarcinoma, NOS (8050,8260) | 404 | 1.5% | 350 | 1.6% | 34 | 1.6% | - | - | - | - | 47 | 1.4% |
| Clear cell adenocarcinoma (8310,9110) | 1,407 | 5.2% | 1,089 | 4.9% | 51 | 2.4% | 257 | 12.7% | - | - | 146 | 4.5% |
| Endometrioid carcinoma (8380-8383,8570) | 2,593 | 9.7% | 2,186 | 9.8% | 121 | 5.6% | 245 | 12.1% | - | - | 353 | 10.8% |
| Cystadenocarcinoma, NOS (8440,8450) | 110 | 0.4% | 88 | 0.4% | - | - | - | - | - | - | - | - |
| Serous cystadenocarcinoma (8441) | 5,601 | 20.9% | 4,798 | 21.5% | 383 | 17.7% | 346 | 17.1% | 35 | 28.0% | 593 | 18.1% |
| Papillary serous cystadenocarcinoma (8460-8462) | 6,307 | 23.5% | 5,435 | 24.4% | 463 | 21.4% | 357 | 17.7% | 30 | 24.0% | 699 | 21.3% |
| Mucinous cystadenocarcinoma (8470-8473) | 403 | 1.5% | 332 | 1.5% | 29 | 1.3% | 35 | 1.7% | - | - | 66 | 2.0% |
| Mucinous adenocarcinoma (8480,8482) | 949 | 3.5% | 756 | 3.4% | 80 | 3.7% | 101 | 5.0% | - | - | 137 | 4.2% |
| Mucin-producing adenocarcinoma(8481) | 48 | 0.2% | 39 | 0.2% | - | - | - | - | - | - | - | - |
| Other adenocarcinomaf | 1,411 | 5.3% | 1,194 | 5.4% | 64 | 3.0% | 133 | 6.6% | - | - | 174 | 5.3% |
| Other specific carcinomasg | 617 | 2.3% | 448 | 2.0% | 120 | 5.5% | 37 | 1.8% | - | - | 103 | 3.1% |
| Stromal cell tumor (8620-8631,8650) | 425 | 1.6% | 294 | 1.3% | 97 | 4.5% | 22 | 1.1% | - | - | 70 | 2.1% |
| Otherh | 192 | 0.7% | 154 | 0.7% | 23 | 1.1% | - | - | - | - | 33 | 1.0% |
| Unspecified, Carcinoma, NOS (8010,8020-8022) | 1,246 | 4.6% | 1,020 | 4.6% | 124 | 5.7% | 86 | 4.3% | - | - | 168 | 5.1% |
| Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582) | 96 | 0.4% | 66 | 0.3% | 20 | 0.9% | - | - | - | - | 20 | 0.6% |
| Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539) | 1,852 | 6.9% | 1,452 | 6.5% | 204 | 9.4% | 168 | 8.3% | - | - | 361 | 11.0% |
| Mullerian mixed tumor (8950-8951,8980) | 806 | 3.0% | 674 | 3.0% | 73 | 3.4% | 49 | 2.4% | - | - | 65 | 2.0% |
| Teratoma, malignant (9080-9085,9102) | 411 | 1.5% | 296 | 1.3% | 54 | 2.5% | 54 | 2.7% | - | - | 146 | 4.5% |
| Other | 635 | 2.4% | 482 | 2.2% | 77 | 3.6% | 65 | 3.2% | - | - | 150 | 4.6% |
| Unspecified (8000-8005) | 286 | 1.1% | 232 | 1.0% | 29 | 1.3% | 19 | 0.9% | - | - | 36 | 1.1% |
| Totald | 26,812 | 100.0% | 22,313 | 100.0% | 2,165 | 100.0% | 2,021 | 100.0% | 125 | 100.0% | 3,276 | 100.0% |
Footnotes:
Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Percents may not sum to 100 due to rounding.
a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.
b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.
e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.
f Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449, 8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.
g Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513, 8561-8562,8575,8580-8671.
h Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.
- Statistic not shown due to fewer than 16 cases during the time period.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.